Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Response to Open Peer Commentaries on "Moral Hazard in Pediatrics".

Brunnquell D, Michaelson CM.

Am J Bioeth. 2016 Aug;16(8):W3-4. doi: 10.1080/15265161.2016.1188180. No abstract available.

PMID:
27366855
2.

Moral Hazard in Pediatrics.

Brunnquell D, Michaelson CM.

Am J Bioeth. 2016 Jul;16(7):29-38. doi: 10.1080/15265161.2016.1180441.

PMID:
27292845
3.

Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis.

Meier EJ, Torkildsen GL, Gow JA, McNamara TR, Gomes PJ, Williams JI; Bepotastine Besilate Ophthalmic Solutions Study Group.

Allergy Asthma Proc. 2012 May-Jun;33(3):265-74.

PMID:
22991696
4.

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge.

Torkildsen GL, Williams JI, Gow JA, Gomes PJ, Abelson MB, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Ann Allergy Asthma Immunol. 2010 Jul;105(1):57-64. doi: 10.1016/j.anai.2010.04.005.

PMID:
20642205
5.

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.

Macejko TT, Bergmann MT, Williams JI, Gow JA, Gomes PJ, McNamara TR, Abelson MB; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Am J Ophthalmol. 2010 Jul;150(1):122-127.e5. doi: 10.1016/j.ajo.2010.02.007. Epub 2010 May 20.

PMID:
20488431
6.

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.

Abelson MB, Torkildsen GL, Williams JI, Gow JA, Gomes PJ, McNamara TR; Bepotastine Besilate Ophthalmic Solutions Clinical Study Group.

Clin Ther. 2009 Sep;31(9):1908-21. doi: 10.1016/j.clinthera.2009.09.001.

PMID:
19843481

Supplemental Content

Loading ...
Support Center